Clinical Pharmacokinetics of Daclatasvir/Sofosbuvir in Adolescents With Hepatitis C Virus
Status:
Unknown status
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
This is an interventional Phase II/III, single center, single arm clinical trial to assess
the pharmacokinetics, efficacy, safety and tolerance of daclatasvir plus sofosbuvir in
treatment-naïve, non-cirrhotic adolescents with chronic HCV GT-4 infection.
A single-arm evaluation of daclatasvir/sofosbuvir will focus on the pharmacokinetics,
efficacy and safety
All enrolled patients will receive daclatasvir 60 mg orally once daily plus sofosbuvir at a
dose of 400 mg orally once daily for 12 weeks.